Aberrant signaling or hyper activation of MAPK pathway has been shown in many tumors including melanomas, non-small cell lung cancer (NSCLC), pancreatic and colorectal cancers, chiefly due to mutations in RAS and BRAF proto-oncogenes (22). This evidence concerns the gene BRAF and non-small cell lung carcinoma.